STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Recipharm AB (STO: RECI)
In November 2014, the number of shares in Recipharm AB (publ) (“Recipharm”) has increased by 3,500,000 shares of series B, corresponding to 3,500,000 votes. The increase in the number of shares and votes results from a share issue in connection with the acquisition of the Lisbon based CDMO Lusomedicameta Sociedade Técnica Farmacêutica S.A. as announced on 13 November 2014.
As of 28 November 2014, the total number of shares in Recipharm amounts to 40,688,875, divided into 12,685,716 shares of series A and 28,003,159 shares of series B. The total number of votes in Recipharm as of 28 November 2014 amounts to 154,860,319.
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980).
This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of Nasdaq Stockholm. This information was submitted for publication on 28 November 2014, at 11:00 am CET.
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 2,100 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.2 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com.
This information was brought to you by Cision http://news.cision.com